Bowel Dose-Volume Predictors of GI Toxicity in Postoperative Radiotherapy for Cervical Cancer
The PARCER trial was a multicenter phase III RCT involving 283 patients with cervical cancer undergoing postoperative radiotherapy with or without chemotherapy. The study compared intensity-modulated radiotherapy (IMRT) versus three-dimensional conformal radiotherapy (3DCRT) techniques. Median follow-up was 43 months.
Main results showed that bowel V30Gy and V40Gy were associated with acute ≥G2 diarrhea, late ≥G2 diarrhea, and persistent GI toxicity. IMRT reduced the risk of late ≥G2 diarrhea and persistent GI toxicity. However, radical hysterectomy with bilateral lymphadenectomy increased the risk of persistent GI toxicity.
Model performance was modest, with AUC values of 0.761 for late ≥G2 diarrhea and 0.588 for persistent GI toxicity. No absolute risk reductions or numbers needed to treat were reported. Safety assessment focused on GI toxicity graded by CTCAEv3.0; serious adverse events and discontinuations were not reported.
Limitations include modest model discrimination and the need for external validation. The study reports associations, not causation. These NTCP models may help individualize radiotherapy planning to reduce GI toxicity, but further research is needed.